Fig. 3.

MEDI3622 treatment increases IFNγ production by NK cells stimulated by antibody-bound tumor cells over a range of ratios. a Enriched human NK cells were incubated with SKOV-3 cells, trastuzumab, and/or MEDI3622, as indicated, for 4 h at 37 °C (effector:target ratio = 10:1). Secreted IFNγ levels were quantified by ELISA. b NK cells were treated as described above and their release of granzyme A and granzyme B were quantified by ELISA. c NK and SKOV-3 cells were incubated over a range of effector:target (E:T) ratios, as indicated. Secreted IFNγ levels are shown as fold change normalized to NK cells exposed to SKOV-3 cells alone. The bar graphs show mean ± SD of 3 independent experiments using separate donors. Statistical significance is indicated as *p < 0.05; **p < 0.01; ***p < 0.001; ****p < 0.0001